India's cancer patients face impossible choice: immunotherapy or survival

Life-saving immunotherapy drugs for head and neck cancers remain out of reach for most patients in India. These treatments, while effective, come with staggering costs that far exceed average incomes. The financial burden often forces families to choose between medical care and basic survival.

Head and neck cancers are a major health concern in India, largely due to tobacco, areca nut, and alcohol use. Immunotherapy drugs like pembrolizumab and nivolumab offer hope by helping the immune system target cancer cells. Yet, their prices create an impossible barrier for many.

A six-month course of pembrolizumab costs nearly 80 times the average monthly income in India. Nivolumab, another immunotherapy option, is priced at over 20 times the average monthly wage for a similar treatment period. With most healthcare expenses paid out of pocket, these costs can push families into deep poverty.

The issue is not a lack of medical progress but pricing that ignores real-world incomes. For the cost of treating one patient with pembrolizumab, 18 to 22 others could receive lower-cost targeted therapies instead. Without pricing reforms, these life-extending treatments will stay beyond the reach of those who need them most.

High drug costs force many Indian families to drain savings or forgo treatment entirely. The gap between medical breakthroughs and affordability leaves patients with few options. Until pricing aligns with local incomes, immunotherapy will remain a privilege rather than a standard care solution.